Boggio et al. demonstrated that high-frequency rTMS (20Hz) of either the right or left cerebral hemisphere can be effective in reducing the symptoms of PTSD. In contrast, some authors have observed that low-frequency rTMS (1 Hz) on the right dorsolateral prefrontal cortex seems to be more effective. Again, however, Cohen et al., upon comparing low-frequency rTMS (1Hz) and high-frequency rTMS (10Hz) on the right dorsolateral prefrontal cortex, concluded that high-frequency rTMS showed greater improvement of
A recent systematic review with pairwise meta-regression explored several stimulation variables, like electrode size, electric current, current density, tDCS duration, number of sessions, electric charge, total electric charge, and total electric charge density . The authors ten comparisons of eight RCTs with 213 participants which measured arm function after stroke. They identified pad size, charge density, and current density as potentially relevant effect modifiers in studies measuring arm function by
Because fatigue is a common complaint with MS, and with no effective treatments to address it, the researchers, encouraged by their findings, note that they may point to a future role for this technology in treating this particular symptom. However, they also caution the need to validate the findings in larger studies—and strongly caution individuals with MS not to try over-the-counter stimulation technologies at home or outside of a rigorous research setting.People with who underwent a noninvasive form
About 75 percent of people with MS report among their most disabling disease symptoms. Medications, such as those that treat narcolepsy, behavior-based therapies, and even exercise programs are often prescribed—but benefits have been found to be unreliable.
The tDCS device used in the study was invented by Marom Bikson, PhD, professor of biomedical engineering at The City College of New York, and Abhishek Datta, PhD, chief technology officer of Soterix Medical, which holds a patent on the device. Dr. Charvet provided Dr. Bikson’s team with feedback from trial participants to make the device more accessible for use with MS. The study was funded by the National MS Society pilot grant PP-1411-02021 and The Lourie Foundation, Inc.